NEUP — Stock Film
STOCK FILMSCENE 1/11NEUP · $4.31
Stock Expert AI presents
NEUP
Neuphoria Therapeutics Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Neuphoria Therapeutics Inc. A quick introduction.

On the stock market since 2021, it operates in the world of health and science. It has 8 employees. Now — the numbers.

on the stock market since 2021
8 employees
$23.3M market value
Revenue last year:
$0
The loss that same year:
$0
Sales don’t cover the costs; the gap drains from the cash pile every year.

The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.

THE SALES TREND
Sales are growing overall, with a pause along the way.

Average growth of 103% a year over the last 4 years. Red columns mark years that ended in a loss.

$928K
2021
$383K
2022
$0
2023
$0
2024
$15.6M
2025
In the vault right now:
$0
DEBT: $226K
At this pace, that money lasts about 58.4 years.

Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
66
strong

Clearly above the class average — a step short of the very top.

FINANCIAL STRENGTH
76
strong

Clearly above the class average — a step short of the very top.

VALUATION
71
strong

Clearly above the class average — a step short of the very top.

GROWTH
87
very strong

Sales are growing strongly for its sector.

PRICE MOMENTUM
19
very weak

Clearly below the class average.

WORTH WATCHING

Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 2 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
Fat profit per sale, but shrinking10/10
WEAK SPOTS
The stock has lost its spark0/10
THE FIVE-YEAR JOURNEY
A long and steep decline.

An investor who bought at the very peak is down 98% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/3
Sales keep climbing

Over the last 3 years, sales grew about 244% a year on average.

2
THE BRIGHT SIDE · 2/3
The product is selling

Sales run at $15.6M a year. A small number, but proof the product has real buyers.

3
THE BRIGHT SIDE · 3/3
Strong cash, light debt

There is $21.6M in the vault; even if every debt were paid off, $21.4M would remain.

1
THE RISKS · 1/2
Small scale, thin loss

A loss of $370K against $15.6M in annual sales.

2
THE RISKS · 2/2
The stock has lost its spark

Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 19/100. For a turnaround signal, the stock first needs to close the gap with the market.

FINALE · THE GRADE
F
0 / 100 · MoonshotScore

On our five-subject report card, NEUP sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: NEUP is a high-risk stock — not yet profitable, and its future rides on its product catching on.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Jul 21, 2026 · stockexpertai.com · Stock Film